CD22 and acute lymphoblastic leukemia: CD22 is expressed in > 90% B-lineage cells in ALL and has a similar expression pattern to CD19 [78, 79], making anti-CD22 therapies suitable for use in event of resistance developing in patients receiving anti-CD19 therapies or for use as a combination therapy.